Related Experiment Video

Updated: Aug 23, 2026

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment
08:49

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure

Larisa H Cavallari1, Lucy A Fashingbauer, Amber L Beitelshees

  • 1Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, 60612-7230, USA. humma@uic.edu

Pharmacotherapy
|June 30, 2004
PubMed

Insights

African-Americans with heart failure had lower serum potassium and needed more supplementation than Caucasians, even with spironolactone. This suggests race impacts spironolactone

Area of Science:

  • Cardiology
  • Pharmacogenomics
  • Nephrology

Background:

  • Spironolactone is a key medication for heart failure management.
  • Potassium homeostasis is crucial for cardiovascular health.
  • Racial disparities in medication response are increasingly recognized.

Purpose of the Study:

  • To investigate if spironolactone's effects on potassium levels differ between African-American and Caucasian patients with heart failure.
  • To compare serum potassium concentrations and potassium supplement use in these groups.

Main Methods:

  • Retrospective medical record review at two heart failure centers.
  • Analysis of 50 African-American and 67 Caucasian patients on stable spironolactone and standard heart failure therapy.
  • Comparison of serum potassium, diuretic use, renal function, and ACE inhibitor/ARB dosages.

Main Results:

  • No significant differences in diuretic therapy or renal function between racial groups.
  • African-Americans had lower serum potassium (4.2 vs 4.5 mEq/L) and higher potassium supplementation rates (48% vs 15%).
  • Spironolactone increased serum potassium more in Caucasians and reduced supplementation needs more in Caucasians compared to African-Americans.

Conclusions:

  • Spironolactone's impact on potassium homeostasis appears to vary by race in heart failure patients.
  • A significant proportion of heart failure patients, especially African-Americans, require potassium supplementation even with spironolactone.
  • Further research into race-based differences in spironolactone response is warranted.
Abstract

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...